Literature DB >> 11325814

Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.

J H Jang1, K H Shin, J G Park.   

Abstract

Autosomal dominant disorders of skeletal and cranial development have been linked to fibroblast growth factor receptor (FGFR) 2 and FGFR3. Here we report two identical mutations in FGFR2 that cause craniosynostosis syndromes, Crouzon, Apert, and Pfeiffer in gastric carcinoma. A missense mutation (Ser267Pro) in exon IIIa and a splice site mutation (940-2A-->G) in exon IIIc were detected in gastric cancer patients. Interestingly, these heterozygous somatic mutations are identical to the germinal activating mutations in FGFR2 reported previously in craniosynostosis syndromes. In addition, the two novel mutations of FGFR3 in colorectal carcinomas were identified. All identified mutations occurred at highly conserved sequences, not only in the FGFR family of molecules, but also throughout evolution and clustered in the immunoglobulin-like loop-III domain, highlighting the functional importance of this domain. Our results indicate that FGFR2 and FGFR3, in addition to their potential role in skeletal dysplasias, play an important role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325814

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  98 in total

Review 1.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

2.  Proliferation of poorly differentiated endometrial cancer cells through autocrine activation of FGF receptor and HES1 expression.

Authors:  Michihiro Mori; Toshinori Mori; Aina Yamamoto; Shoji Takagi; Masatsugu Ueda
Journal:  Hum Cell       Date:  2019-04-08       Impact factor: 4.174

3.  Fibronectin-mediated adhesion rescues cell cycle arrest induced by fibroblast growth factor-1 by decreased expression of p21(cip/waf) in human chondrocytes.

Authors:  Jun-Hyeog Jang; Chong-Pyoung Chung
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 May-Jun       Impact factor: 2.416

4.  A structure-guided approach to creating covalent FGFR inhibitors.

Authors:  Wenjun Zhou; Wooyoung Hur; Ultan McDermott; Amit Dutt; Wa Xian; Scott B Ficarro; Jianming Zhang; Sreenath V Sharma; Joan Brugge; Matthew Meyerson; Jeffrey Settleman; Nathanael S Gray
Journal:  Chem Biol       Date:  2010-03-26

Review 5.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

6.  FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation.

Authors:  Miriam S Udler; Kerstin B Meyer; Karen A Pooley; Eric Karlins; Jeffery P Struewing; Jinghui Zhang; David R Doody; Stewart MacArthur; Jonathan Tyrer; Paul D Pharoah; Robert Luben; Leslie Bernstein; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Giske Ursin; Michael F Press; Paul Brennan; Suleeporn Sangrajrang; Valerie Gaborieau; Fabrice Odefrey; Chen-Yang Shen; Pei-Ei Wu; Hui-Chun Wang; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Bruce A J Ponder; Christopher A Haiman; Kathleen E Malone; Alison M Dunning; Elaine A Ostrander; Douglas F Easton
Journal:  Hum Mol Genet       Date:  2009-02-17       Impact factor: 6.150

7.  FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations.

Authors:  Leon Raskin; Mila Pinchev; Chana Arad; Flavio Lejbkowicz; Ada Tamir; Hedy S Rennert; Gad Rennert; Stephen B Gruber
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-05       Impact factor: 4.254

8.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

Review 9.  Polygenic susceptibility to breast cancer: current state-of-the-art.

Authors:  Maya Ghoussaini; Paul D P Pharoah
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

10.  Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

Authors:  Do-Hee Kim; Yeonui Kwak; Nam Doo Kim; Taebo Sim
Journal:  Cancer Biol Ther       Date:  2016       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.